Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Pipeline Insight 2029

September 2023 | 900 pages | ID: G99CDF572B47EN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Pipeline Insight 2029 Report Findings:

• Global Controlled Release Drugs Delivery Market Opportunity: > USD 100 Billion By 2029
• Insight On Drugs Commercially Available In Market: > 150 Drugs
• Global Controlled Release Drug Clinical Trials Insight: > 230 Drugs
• Controlled Release Drug Clinical Trials Insight By Company, Country , Indication & Phase
• Drug Dosage, Patent, Pricing & Sales Insight By Indication
• Global Controlled Release Drug Regional Market Trends: USA, Europe, Japan, China Canada & South Korea
• Insight On Key 30 Companies

The concept of controlled release formulations in the pharmaceutical market is a rapidly emerging trend, attracting significant investments from key market players. To combat generic competition, pharmaceutical companies are actively developing sustained release and controlled release versions of their popular drugs, thereby driving the market forward. The administration of controlled release drugs offers several advantages, including reduced dosage and frequency, minimized fluctuations in drug levels, enhanced efficacy, improved patient adherence, and consistent therapeutic effects. By utilizing controlled release drug delivery systems, drugs can be released at specific target sites at predetermined intervals, resulting in predictable release kinetics and prolonged therapeutic benefits compared to conventional administration methods. As a result of these additional advantages, the use of controlled release delivery systems is expected to experience significant growth in the forecast period.

Traditional immediate release formulations often fail to provide the desired pharmacokinetic profiles required for optimal treatment. However, the advent of controlled release drug delivery systems has revolutionized the way medications are administered. These innovative approaches offer numerous advantages, including sustained drug release, targeted delivery, and improved patient compliance. In this article, we delve into the world of controlled release drug delivery and explore its significant impact on patient care. One of the key benefits of controlled release drug delivery systems is their ability to improve drug efficacy. By maintaining sustained therapeutic drug levels, these systems ensure a consistent and prolonged action of the medication. This is particularly crucial for the treatment of chronic conditions or diseases that require continuous drug exposure. Controlled release systems can help achieve therapeutic concentrations over extended periods, effectively managing symptoms, and improving long-term outcomes.

Many medications display a narrow therapeutic window, meaning that the optimal dose lies between a ranges where efficacy is achieved without causing excessive side effects. Immediate-release formulations can lead to rapid drug absorption, resulting in high peak concentrations that may contribute to adverse reactions. Controlled release systems, on the other hand, offer a more controlled and gradual release of the drug, minimizing peak concentrations and reducing the risk of side effects. By providing a more stable drug concentration, these systems contribute to a better tolerability profile, ensuring patient safety and comfort.

Keeping to prescribed medication regimens is a crucial factor in achieving successful treatment outcomes. However, the need for frequent dosing can often pose challenges for patients, leading to non-compliance. Controlled release drug delivery systems address this issue by reducing the dosing frequency. Patients can benefit from prolonged drug action, resulting in fewer administrations and enhanced convenience. This improved compliance not only simplifies treatment regimens but also enhances patient satisfaction and overall treatment success. In many disease conditions, it is desirable to deliver drugs specifically to the affected tissues or cells, while minimizing exposure to healthy tissues. Controlled release drug delivery systems enable targeted drug delivery by employing various strategies. Nanoparticles, liposomes, and other carrier systems can be engineered to specifically accumulate in the desired site, such as tumor tissues in cancer therapy. This targeted approach enhances drug efficacy while reducing off-target effects, ultimately leading to improved therapeutic outcomes.

The field of controlled release drug delivery continues to evolve, with ongoing advancements in technology and research. Scientists are exploring novel materials, such as stimuli responsive polymers, that can release drugs in response to specific triggers within the body. Additionally, the integration of smart sensors and monitoring devices in these systems holds the potential for personalized medicine, enabling real-time feedback and adaptive drug release. These innovations have the potential to revolutionize disease management and bring about a new era of precision medicine.

Controlled release drug delivery systems have revolutionized patient care by providing sustained and targeted drug delivery, optimizing treatment outcomes, and improving quality of life. From enhancing drug efficacy to reducing side effects and improving patient compliance, these systems have significantly advanced the field of pharmacotherapy. As researchers continue to push the boundaries of innovation, we can anticipate further breakthroughs that will shape the future of controlled release drug delivery, bringing us closer to personalized, effective, and safer therapeutic interventions for a wide range of medical conditions.

Contents

1. INTRODUCTION TO CONTROLLED DRUG DELIVERY

1.1 Fundamentals & Technology Of Controlled Drug Delivery Systems
1.2 Controlled Drug Delivery Classification: By System, Route & Technology
1.3 Controlled Drug Delivery Mechanism of Action

2. MATERIAL BASED APPROACHES FOR CONTROLLED DRUG DELIVERY

2.1 Polymers
2.2 Chronopharmaceutics
2.3 Nanoparticulate Delivery System

3. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET TRENDS

3.1 Current Market Scenario
3.2 Future Market Outlook

4. GLOBAL CONTROLLED RELEASE DRUG REGIONAL MARKET TRENDS

4.1 US
4.2 Europe
4.3 Japan
4.4 China
4.5 Canada
4.6 South Korea

5. GLOBAL CONTROLLED RELEASE DRUGS CLINICAL PIPELINE OVERVIEW

5.1 Company
5.2 Country
5.3 Drug Class
5.4 Indication
5.5 Patient Segment
5.6 Phase

6. CONTROLLED DRUG DELIVERY RESEARCH & CLINICAL TRENDS BY INDICATION

6.1 Diabetes
6.2 Cancer
6.3 Cardiovascular Diseases
6.4 Neurological Disorders
6.5 Infections

7. GLOBAL CONTROLLED RELEASE DRUGS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered

8. MARKETED CONTROLLED RELEASE DRUGS CLINICAL INSIGHT


9. CONTROLLED RELEASE DRUGS FOR ALZHEIMER’S DISEASE - PRICING, PATENT & DOSAGE INSIGHT

9.1 Namzaric (Extended-Release)
9.2 Namenda XR (Extended-Release)
9.3 Razadyne ER (Extended-Release)

10. CONTROLLED RELEASE DRUGS FOR PARKINSON’S DISEASE - PRICING, PATENT & DOSAGE INSIGHT

10.1 Gocovri (Extended-Release)
10.2 Osmolex ER (Extended-Release)
10.3 Mirapex ER (Extended-Release)

11. CONTROLLED RELEASE DRUGS FOR SCHIZOPHRENIA - PRICING, PATENT & DOSAGE INSIGHT

11.1 Perseris (Extended-Release)
11.2 Invega (Extended-Release)
11.3 Invega Sustenna/Invega Trinza/Invega Hafyera (Extended-Release)
11.4 Seroquel XR (Extended-Release)
11.5 Abilify Maintena/ Abilify Asimtufii (Extended-Release)
11.6 Aristada/Aristada Initio (Extended-Release)
11.7 Rykindo (Extended-Release)
11.8 Uzedy (Extended-Release)

12. CONTROLLED RELEASE DRUGS FOR CHRONIC PAIN - PRICING, PATENT & DOSAGE INSIGHT

12.1 Hysingla ER (Extended-Release)
12.2 Nucynta ER (Extended-Release)
12.3 Kadian (Extended-Release)
12.4 Xtampza ER (Extended-Release)
12.5 MS Contin (Extended-Release)
12.6 Embeda (Extended-Release)

13. CONTROLLED RELEASE DRUGS FOR MULTIPLE SCLEROSIS - PRICING, PATENT & DOSAGE INSIGHT

13.1 Ampyra/Fampyra (Extended-Release)
13.2 Tecfidera (Delayed-Release)
13.3 Rayos (Delayed-Release)
13.4 Vumerity (Delayed-Release)
13.5 Bafiertam (Delayed-Release)

14. CONTROLLED RELEASE DRUGS FOR DIABETES MELLITUS TYPE II - PRICING, PATENT & DOSAGE INSIGHT

14.1 Glumetza (Extended-Release)
14.2 Glucotrol XL (Extended-Release)
14.3 Glucophage XR (Extended-Release)
14.4 Bydureon (Extended-Release)
14.5 Trijardy XR (Extended-Release)

15. CONTROLLED RELEASE DRUGS FOR HYPERTENSION & ANGINA PECTORIS - PRICING, PATENT & DOSAGE INSIGHT

15.1 Procardia XL (Extended-Release)
15.2 Toprol XL (Extended-Release)
15.3 Adalat CC (Extended-Release)
15.4 Verelan PM (Extended-Release)
15.5 Cardizem LA (Extended-Release)

16. CONTROLLED RELEASE DRUGS FOR POST-OPERATIVE PAIN - PRICING, PATENT & DOSAGE INSIGHT

16.1 Zynrelef (Extended-Release)
16.2 Posimir (Sustained - Release)

17. CONTROLLED RELEASE DRUGS FOR HIV - PRICING, PATENT & DOSAGE INSIGHT

17.1 Apretude extended-release
17.2 Cabenuva extended-release
17.3 Rukobia (Extended-Release)

18. CONTROLLED RELEASE DRUGS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER - PRICING, PATENT & DOSAGE INSIGHT

18.1 Qelbree (extended-release)
18.2 Jornay PM (Extended-Release)
18.3 Cotempla XR-ODT (Extended-Release)
18.4 Adzenys ER (Extended-Release)

19. CONTROLLED RELEASE DRUGS FOR INFLAMMATORY & AUTOIMMUNE DISEASES - PRICING, PATENT & DOSAGE INSIGHT

19.1 Rinvoq (Extended-Release)
19.2 Ortikos (Extended-Release)
19.3 Xeljanz XR (Extended-Release)

20. CONTROLLED RELEASE DRUGS FOR BACTERIAL INFECTIONS - PRICING, PATENT & DOSAGE INSIGHT

20.1 Aemcolo (Delayed-Release)
20.2 Talicia (Delayed-Release)

21. CONTROLLED RELEASE DRUGS FOR OPIOID USE DISORDER - PRICING, PATENT & DOSAGE INSIGHT

21.1 Sublocade (Sustained-Release)
21.2 Brixadi (Extended-Release)

22. CONTROLLED RELEASE DRUGS FOR PREVENTING ORGAN TRANSPLANT REJECTION - PRICING, PATENT & DOSAGE INSIGHT

22.1 Astagraf XL (Extended-Release)
22.2 Envarsus XR (Extended-Release)

23. GLOBAL CONTROLLED DRUG DELIVERY MARKET DYNAMICS

23.1 Market Drivers
23.2 Market Restraints

24. COMPETITIVE LANDSCAPE

24.1 AbbVie
24.2 Antlia Bioscience
24.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
24.4 AstraZeneca
24.5 Bausch Health Companies
24.6 Biodexa Pharmaceuticals
24.7 Camurus
24.8 DURECT Corporation
24.9 Emplicure
24.10 Endo International
24.11 HLK Pharmacin
24.12 Jemincare
24.13 Johnson & Johnson
24.14 Luye Pharma Group
24.15 Lyndra
24.16 Mallinckrodt plc
24.17 MedinCell S.A.
24.18 Merck
24.19 Otsuka Pharmaceutical
24.20 Pacira BioSciences
24.21 Pfizer
24.22 Purdue Pharma
24.23 Roche
24.24 Sanofi
24.25 Serina Therapeutics
24.26 Sun Pharmaceutical Industries
24.27 Supernus Pharmaceuticals
24.28 Takeda
24.29 Tris Pharma
24.30 ViiV Healthcare
Table 1-1: Major Differences between Conventional & Novel Drug Delivery Systems
Table 1-2: Comparison of Sustained Drug Release & Controlled Drug Release
Table 4-1: US FDA – Some Recently Approved Controlled Release Drugs